Arcadia Biosciences (RKDA) Total Non-Current Liabilities (2014 - 2025)

Arcadia Biosciences (RKDA) has 12 years of Total Non-Current Liabilities data on file, last reported at $2.4 million in Q4 2025.

• Quarterly Total Non-Current Liabilities fell 54.55% year-over-year to $2.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.4 million (down 54.55% YoY) and the FY2025 annual result came in at $2.4 million, down 54.55% from the prior year.
• Total Non-Current Liabilities slipped to $2.4 million in Q4 2025, from $3.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $26.0 million in Q2 2021 to a low of $2.4 million in Q4 2025.
• A 5-year average of $8.0 million and a median of $6.0 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities plunged 75.98% — and 2023, when it surged 79.78%.
• Tracing RKDA's Total Non-Current Liabilities over 5 years: stood at $10.7 million in 2021, then tumbled by 43.47% to $6.0 million in 2022, then declined by 16.94% to $5.0 million in 2023, then grew by 5.84% to $5.3 million in 2024, then tumbled by 54.55% to $2.4 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $2.4 million (Q4 2025), $3.1 million (Q3 2025), and $3.3 million (Q2 2025), per Business Quant data.